Skip Nav Destination
Issues
15 March 2014
-
Cover Image
Cover Image
The cover shows a section of an intracranial glioblastoma (GBM); GBM cells express the fluorescent protein citrine (green) and the High-mobility group protein B1 (HMGB1) fused to the red fluorescent protein cherry. In living cells HMGB1 is located in the nucleus; upon cell death, HMGB1 is translocated to the cytoplasm and is eventually secreted. Circulating levels of HMGB1 may constitute a noninvasive surrogate biomarker of therapeutic efficacy. For details, see the article by Candolfi and colleagues on page 1555 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
Statistics in Clinical Cancer Research
Molecular Pathways
CCR Focus
Evidence of Clinical Utility: An Unmet Need in Molecular Diagnostics for Patients with Cancer
David R. Parkinson; Robert T. McCormack; Susan M. Keating; Steven I. Gutman; Stanley R. Hamilton; Elizabeth A. Mansfield; Margaret A. Piper; Patricia DeVerka; Felix W. Frueh; J. Milburn Jessup; Lisa M. McShane; Sean R. Tunis; Caroline C. Sigman; Gary J. Kelloff
Human Cancer Biology
hERG1 Channels Regulate VEGF-A Secretion in Human Gastric Cancer: Clinicopathological Correlations and Therapeutical Implications
Olivia Crociani; Elena Lastraioli; Luca Boni; Serena Pillozzi; Maria Raffaella Romoli; Massimo D'Amico; Matteo Stefanini; Silvia Crescioli; Antonio Taddei; Lapo Bencini; Marco Bernini; Marco Farsi; Stefania Beghelli; Aldo Scarpa; Luca Messerini; Anna Tomezzoli; Carla Vindigni; Paolo Morgagni; Luca Saragoni; Elisa Giommoni; Silvia Gasperoni; Francesco Di Costanzo; Franco Roviello; Giovanni De Manzoni; Paolo Bechi; Annarosa Arcangeli
Cancer Therapy: Preclinical
Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease
Antonio Garcia-Gomez; Dalia Quwaider; Miriam Canavese; Enrique M. Ocio; Ze Tian; Juan F. Blanco; Allison J. Berger; Carlos Ortiz-de-Solorzano; Teresa Hernández-Iglesias; Anton C.M. Martens; Richard W.J. Groen; Joaquín Mateo-Urdiales; Susana Fraile; Miguel Galarraga; Dharminder Chauhan; Jesús F. San Miguel; Noopur Raje; Mercedes Garayoa
Imaging, Diagnosis, Prognosis
Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A–Specific T Cells
Benjamin Weide; Alexander Martens; Henning Zelba; Christina Stutz; Evelyna Derhovanessian; Anna Maria Di Giacomo; Michele Maio; Antje Sucker; Bastian Schilling; Dirk Schadendorf; Petra Büttner; Claus Garbe; Graham Pawelec
Author Choice
Radiation-Enhanced Lung Cancer Progression in a Transgenic Mouse Model of Lung Cancer Is Predictive of Outcomes in Human Lung and Breast Cancer
Oliver Delgado; Kimberly G. Batten; James A. Richardson; Xian-Jin Xie; Adi F. Gazdar; Aadil A. Kaisani; Luc Girard; Carmen Behrens; Milind Suraokar; Gail Fasciani; Woodring E. Wright; Michael D. Story; Ignacio I. Wistuba; John D. Minna; Jerry W. Shay
EASL- and mRECIST-Evaluated Responses to Combination Therapy of Sorafenib with Transarterial Chemoembolization Predict Survival in Patients with Hepatocellular Carcinoma
Lei Liu; Weijuan Wang; Hui Chen; Yan Zhao; Wei Bai; Zhanxin Yin; Chuangye He; Jia Jia; Man Yang; Jielai Xia; Daiming Fan; Guohong Han
Cancer Therapy: Clinical
A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors
Jhanelle E. Gray; Eric Haura; Alberto Chiappori; Tawee Tanvetyanon; Charles C. Williams; Mary Pinder-Schenck; Julie A. Kish; Jenny Kreahling; Richard Lush; Anthony Neuger; Leticia Tetteh; Angela Akar; Xiuhua Zhao; Michael J. Schell; Gerold Bepler; Soner Altiok
Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies
Daniel W. Bowles; Jennifer R. Diamond; Elaine T. Lam; Colin D. Weekes; David P. Astling; Ryan T. Anderson; Stephen Leong; Lia Gore; Marileila Varella-Garcia; Brian W. Vogler; Stephen B. Keysar; Elizabeth Freas; Dara L. Aisner; Chen Ren; Aik-Chook Tan; Francois Wilhelm; Manoj Maniar; S. Gail Eckhardt; Wells A. Messersmith; Antonio Jimeno
Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies
Ravi Salgia; Premal Patel; John Bothos; Wei Yu; Steve Eppler; Priti Hegde; Shuang Bai; Surinder Kaur; Ihsan Nijem; Daniel V.T. Catenacci; Amy Peterson; Mark J. Ratain; Blase Polite; Janice M. Mehnert; Rebecca A. Moss
Predictive Biomarkers and Personalized Medicine
A Functional Germline Variant in GLI1 Implicates Hedgehog Signaling in Clinical Outcome of Stage II and III Colon Carcinoma Patients
Joanna Szkandera; Martin Pichler; Gudrun Absenger; Michael Stotz; Melanie Weissmueller; Hellmut Samonigg; Martin Asslaber; Sigurd Lax; Gerhard Leitner; Thomas Winder; Wilfried Renner; Armin Gerger
Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA
Geoffrey R. Oxnard; Cloud P. Paweletz; Yanan Kuang; Stacy L. Mach; Allison O'Connell; Melissa M. Messineo; Jason J. Luke; Mohit Butaney; Paul Kirschmeier; David M. Jackman; Pasi A. Jänne
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds